Beyond group classification: probabilistic differential diagnosis of frontotemporal dementia and Alzheimer’s disease with MRI and CSF biomarkers.

Author:

Pérez-Millan Agnès1,Thirion Bertrand2,Falgàs Neus1,Borrego-Écija Sergi1,Bosch Beatriz1,Juncà-Parella Jordi1,Tort-Merino Adrià1,Sarto Jordi1,Augé Josep Maria1,Antonell Anna1,Bargalló Nuria1,Balasa Mircea1,Lladó Albert1,Sánchez-Valle Raquel1,Sala-Llonch Roser3

Affiliation:

1. Hospital Clínic de Barcelona

2. Inria Saclay - Île-de-France Research Centre

3. University of Barcelona

Abstract

Abstract Background Neuroimaging and fluid biomarkers are used in clinics to differentiate frontotemporal dementia (FTD) from Alzheimer’s disease (AD) and other neurodegenerative and non-neurodegenerative disorders. We implemented a machine learning (ML) algorithm that provides individual probabilistic scores for these patients based on magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) data. Methods We used a calibrated classifier with a Support Vector Machine with MRI data. We obtained group classifications and individual probabilities associated with group correspondence. We used the individual probabilities to address the clinical problem of confidence in the diagnosis. We investigated whether combining MRI and CSF levels of Neurofilament light (NfL) and 14-3-3 could improve the diagnosis confidence. Results 215 AD patients (65 ± 10 years, 137 women), 103 FTD patients (64 ± 8 years, 49 women), and 173 healthy controls (CTR) (59 ± 15 years, 106 women) were studied. With MRI data only, we obtained accuracies of 88% in the AD vs. healthy controls (CTR) classification, 87% for FTD vs. CTR, 82% for AD vs. FTD, and 80% when differentiating the three groups. A total of 74% of FTD and 73% of AD participants have a high (≥ 0.8) probability of accurate diagnosis in the FTD vs. AD comparison. Adding CSF-NfL and 14-3-3 levels slightly improved the accuracy and the number of patients in the high diagnosis confidence group. Conclusion We propose a ML algorithm that provides individual diagnostic probabilities, and we validate it using MRI and/or CSF data. Our solution holds promise towards clinical applications as support to clinical findings or in settings with limited access to expert diagnoses.

Publisher

Research Square Platform LLC

Reference60 articles.

1. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;Albert MS;Alzheimer’s and Dementia,2011

2. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;McKhann GM;Alzheimer’s and Dementia,2011

3. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration;Alcolea D;Neurology,2017

4. Antonell A, Tort-Merino A, Ríos J, Balasa M, Borrego-Écija S, Auge JM, et al. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer’s & Dementia [Internet]. 2019 Oct 24 [cited 2022 Dec 7]; Available from: https://www.sciencedirect.com/science/article/pii/S1552526019353695

5. Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology;McFerrin MB;Ann Clin Transl Neurol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3